



November 8, 2019

✓ **The BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of U.S. FDA approval for the Company's Zileuton Extended-Release Tablets, 600 mg, to market a generic equivalent of Zylflo CR® Extended-Release Tablets, 600 mg of Chiesi USA, Inc., indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**



Encl.: a/a



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin receives US FDA approval for Zileuton Extended-Release Tablets

**Mumbai, Baltimore, November 08, 2019:** Pharma major Lupin Limited (Lupin) announced that it has received approval for its Zileuton Extended-Release Tablets, 600 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Zylflo CR® Extended-Release Tablets, 600 mg, of Chiesi USA, Inc.

Lupin's Zileuton Extended-Release Tablets, 600 mg are indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileuton Extended-Release Tablets, 600 mg had annual sales of approximately USD 43 million in the U.S. (IQVIA MAT September 2019).

### About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8<sup>th</sup> largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3<sup>rd</sup> largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3<sup>rd</sup> largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); 6<sup>th</sup> largest company in the Indian Pharmaceutical Market and 5<sup>th</sup> largest generic pharmaceutical player in Japan (IQVIA MAT September 2019).

For the financial year ended March 31, 2019, Lupin's Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter at – [www.twitter.com/lupinglobal](https://www.twitter.com/lupinglobal)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

### For further information or queries please contact –

Arvind Bothra

Head – Investor Relations and M&A / Corporate Communications

Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

Ph: +91-22-66408237

### \*Safe Harbor Statement

Zylflo CR® is a registered trademark of Chiesi USA, Inc.